Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thialbarbital SCHEMBL714642 | 1.00 | ALDH1A1 (0.32) | ALDH1A1 | |
| Thialbarbital SCHEMBL11110725 | 1.00 | ALDH1A1 (0.32) | ALDH1A1 | |
| Thialbarbital SCHEMBL19436260 | 0.99 | ALDH1A1 (0.31) | ALDH1A1 | |
| Thialbarbital SCHEMBL1004175 | 0.84 | MMP9 (0.45) | — | |
| SCHEMBL1642994 | 0.82 | MMP9 (0.35) | — | |
| SCHEMBL713311 | 0.82 | MMP9 (0.35) | — | |
| SCHEMBL9452872 | 0.81 | MMP9 (0.34) | — | |
| Hydrochloric Acid SCHEMBL16927556 | 0.81 | MMP9 (0.34) | — | |
| Cyclobarbital SCHEMBL7617865 | 0.69 | MEN1 (0.31) | — | |
| SCHEMBL8822651 | 0.63 | GAA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240099995-A1 | METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION | PHEBRA PTY LTD (AU) | 2024-03-28 | — | — | US | claimed |
| EP-4291171-A1 | METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION | Phebra Pty Ltd (AU) | 2023-12-20 | — | — | EP | claimed |
| US-20170348303-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140030322-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2014-01-30 | — | — | US | claimed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | claimed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | claimed |
| US-20050152957-A1 | Compositions and delivery systems for administration of a local anesthetic agent | CORIUM INTERNATIONAL (US) | 2005-07-14 | — | — | US | claimed |
| US-20030027833-A1 | Compositions and delivery systems for administration of a local anesthetic agent | CORIUM INTERNATIONAL, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2002089849-A1 | COMPOSITIONS AND DELIVERY SYSTEMS FOR ADMINISTRATION OF A LOCAL ANESTHETIC AGENT | CORIUM INTERNATIONAL (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | ALDH1A1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.